[1] Dirks PB.  Brain tumor stem cells: bringing order to the chaos of brain cancer[J]. J Clin Oncol, 2008, 26(17): 2916-2924.   doi: 10.1200/JCO.2008.17.6792
[2] Louis DN, Perry A, Reifenberger G, et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary[J]. Acta Neuropathol, 2016, 131(6): 803-820.   doi: 10.1007/s00401-016-1545-1
[3] Glioma Meta-analysis Trialists (GMT) Group.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials[J]. Lancet, 2002, 359(9311): 1011-1018.   doi: 10.1016/S0140-6736(02)08091-1
[4] Wu HM, Huang SC, Choi Y, et al.  A Modeling Method to Improve Quantitation of Fluorodeoxyglucose Uptake in Heterogeneous Tumor Tissue[J]. J Nucl Med, 1995, 36(2): 297-306.
[5] Hutterer M, Nowosielski M, Putzer D, et al.  O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma[J]. J Nucl Med, 2011, 52(6): 856-864.   doi: 10.2967/jnumed.110.086645
[6] Jeong SY, Lim SM.  Comparison of 3′-deoxy-3′-[18F] fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma[J]. Nucl Med Biol, 2012, 39(7): 977-981.   doi: 10.1016/j.nucmedbio.2012.02
[7] 理东丽, 许乙凯, 王全师, 等.  11C-MET和18F-FDG PET/CT对胶质瘤诊断的价值比较[J]. 核技术, 2011, 34(2): 151-155.
Li DL, Xu YK, Wang QS, et al.  Comparative PET/CT study with 11C-MET and 18F-FDG for diagnosing glioma[J]. Nucl Tech, 2011, 34(2): 151-155.
[8] Oehme L, Perick M, Beuthien-Baumann B, et al.  Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with 18F-dopa brain PET in normal controls and patients with Parkinson's disease[J]. Eur J Nucl Med Mol Imaging, 2011, 38(8): 1550-1559.   doi: 10.1007/s00259-011-1819-8
[9] Fueger BJ, Czernin J, Cloughesy T, et al.  Correlation of 6-18F-Fluoro-l-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas[J]. J Nucl Med, 2010, 51(10): 1532-1538.   doi: 10.2967/jnumed.110.078592
[10] Tripathi M, Sharma R, D'Souza M, et al.  Comparative Evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for Metabolic Imaging of Low Grade Gliomas[J]. Clin Nucl Med, 2009, 34(12): 878-83.   doi: 10.1097/RLU.0b013e3181becfe0
[11] 黄世明, 罗燕薇, 李彦峰, 等.  18F-FDOPA与18F-FDG PET/CT诊断脑肿瘤的系统评价[J]. 武警医学, 2017, 28(6): 573-577.   doi: 10.14010/j.cnki.wjyx.2017.06.011
Huang SM, Luo YW, Li YF, et al.  A systematic comparison of 18F-FDOPA PET/CT with 18F-FDG PET/CT for diagnosis of brain tumors[J]. Med J Chin PAP, 2017, 28(6): 573-577.   doi: 10.14010/j.cnki.wjyx.2017.06.011
[12] Liu RS, Chang CP, Chu LS, et al.  PET imaging of brain astrocytoma with 1-11C-acetate[J]. Eur J Nucl Med Mol Imaging, 2006, 33(4): 420-427.   doi: 10.1007/s00259-005-0023-0
[13] Tsuchida T, Takeuchi H, Okazawa H, et al.  Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET[J]. Nucl Med Biol, 2008, 35(2): 171-176.   doi: 10.1016/j.nucmedbio.2007.11.004
[14] Yamamoto Y, Nishiyama Y, Kimura N, et al.  11C-Acetate PET in the Evaluation of Brain Glioma: Comparison with 11C-Methionine and 18F-FDG-PET[J]. Mol Imaging Biol, 2008, 10(5): 281-287.   doi: 10.1007/s11307-008-0152-5
[15] Kim S, Kim D, Kim SH, et al.  The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma[J]. Eur J Nucl Med Mol Imaging, 2018, 45(6): 1012-1020.   doi: 10.1007/s00259-018-3948-9
[16] Wardak M, Schiepers C, Cloughesy TF, et al.  18F-FLT and 18F-FDOPA PET Kinetics in Recurrent Brain Tumors[J]. Eur J Nucl Med Mol Imaging, 2014, 41(6): 1199-1209.   doi: 10.1007/s00259-013-2678-2
[17] Shields AF, Grierson JR, Dohmen BM, et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography[J]. Nat Med, 1998, 4(11): 1334-1336.   doi: 10.1038/3337
[18] Saga T, Kawashima H, Araki N, et al.  Evaluation of Primary Brain Tumors With FLT-PET: Usefulness and Limitations[J]. Clin Nucl Med, 2006, 31(12): 774-780.   doi: 10.1097/01.rlu.0000246820.14892.d2
[19] Hong IK, Kim JH, Ra YS, et al.  Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor[J]. J Comput Assist Tomogr, 2011, 35(6): 679-684.   doi: 10.1097/RCT.0b013e3182345b0e
[20] Weber MA, Henze M, Tüttenberg J, et al.  Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?[J]. Invest Radiol, 2010, 45(12): 755-768.   doi: 10.1097/RLI.0b013e3181ec9db0
[21] Lodge MA, Holdhoff M, Leal JP, et al.  Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma[J]. J Nucl Med, 2017, 58(3): 393-398.   doi: 10.2967/jnumed.116.178434
[22] Collet S, Valable S, Constans JM, et al.  [18F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas[J]. NeuroImage Clin, 2015, 8: 448-454.   doi: 10.1016/j.nicl.2015.05.012
[23] Yamamoto Y, Ono Y, Aga F, et al.  Correlation of 18F-FLT Uptake with Tumor Grade and Ki-67 Immunohistochemistry in Patients with Newly Diagnosed and Recurrent Gliomas[J]. J Nucl Med, 2012, 53(12): 1911-1915.   doi: 10.2967/jnumed.112.104729
[24] Brockenbrough JS, Souquet T, Morihara JK, et al.  Tumor 3'-Deoxy-3'-18F-Fluorothymidine (18F-FLT) Uptake by PET Correlates with Thymidine Kinase 1 Expression: Static and Kinetic Analysis of 18F-FLT PET Studies in Lung Tumors[J]. J Nucl Med, 2011, 52(8): 1181-1188.   doi: 10.2967/jnumed.111.089482
[25] Spence AM, Muzi M, Link JM, et al.  NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy of 3′-Deoxy-3′-[18F]fluorothymidine (FLT) as a Marker of Proliferation in Patients with Recurrent Gliomas: Preliminary Efficacy Studies[J]. Mol Imaging Biol, 2009, 11(5): 343-355.   doi: 10.1007/s11307-009-0215-2
[26] Enslow MS, Zollinger LV, Morton KA, et al.  Comparison of 18F-Fluorodeoxyglucose and 18F-Fluorothymidine PET in Differentiating Radiation Necrosis from Recurrent Glioma[J]. Clin Nucl Med, 2012, 37(9): 854-861.   doi: 10.1097/RLU.0b013e318262c76a
[27] Mitamura K, Yamamoto Y, Kudomi N, et al.  Intratumoral heterogeneity of 18F-FLT uptake predicts proliferation and survival in patients with newly diagnosed gliomas[J]. Ann Nucl Med, 2017, 31(1): 46-52.   doi: 10.1007/s12149-016-1129-0
[28] Chen W, Delaloye S, Silverman DHS, et al.  Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation with [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study[J]. J Clin Oncol, 2007, 25(30): 4714-4721.   doi: 10.1200/JCO.2006.10.5825
[29] Zhao F, Cui YF, Li MH, et al.  Prognostic value of 3’-Deoxy-3’-18F-Fluorothymidine ([18F] FLT PET) in patients with recurrent malignant gliomas[J]. Nucl Med Biol, 2014, 41(8): 710-715.   doi: 10.1016/j.nucmedbio.2014.04.134
[30] Pope WB, Young JR, Ellingson BM.  Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy[J]. Curr Neurol Neurosci Rep, 2011, 11(3): 336-344.   doi: 10.1007/s11910-011-0179-x
[31]

Zhao F, Li MH, Wang ZH, et al. 18F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI[J/OL]. PLoS One, 2015, 10(3): e0118769 [2018−08−01]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118769. DOI: 10.1371/journal.pone.0118769.

[32] Schwarzenberg J, Czernin J, Cloughesy TF, et al.  3'-Deoxy-3'-18F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab[J]. J Nucl Med, 2012, 53(1): 29-36.   doi: 10.2967/jnumed.111.092387
[33] Bollineni VR, Collette S, Liu Y.  Functional and molecular imaging in cancer drug development[J]. Chin Clin Oncol, 2014, 3(2): 17-.   doi: 10.3978/j.issn.2304-3865.2014.05.05
[34] Idema AJS, Hoffmann AL, Boogaarts HD, et al.  3'-Deoxy-3'-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients[J]. J Nucl Med, 2012, 53(12): 1904-1910.   doi: 10.2967/jnumed.112.105544
[35] Li ZP, Yu Y, Zhang HH, et al.  A meta-analysis comparing 18F-FLT PET with 18F-FDG PET for assessment of brain tumor recurrence[J]. Nucl Med Commun, 2015, 36(7): 695-701.   doi: 10.1097/MNM.0000000000000302
[36] Belohlavek O, Fencl P, Majovsky M, et al.  FLT-PET in previously untreated patients with low-grade glioma can predict their overall survival[J]. Nucl Med Rev, 2014, 17(1): 7-12.   doi: 10.5603/NMR.2014.0003
[37] Chen W, Cloughesy T, Kamdar N, et al.  Imaging Proliferation In Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG[J]. J Nucl Med, 2005, 46(6): 945-952.
[38]

Toyota Y, Miyake K, Kawai N, et al. Comparison of 4′-[methyl-11C]thiothymidine (11C-4DST) and 3′-deoxy-3′-[18F] fluorothymidine (18F-FLT) PET/CT in human brain glioma imaging[J/OL]. EJNMMI Res, 2015, 5: 7[2018−08-01]. https://www.ncbi.nlm.nih.gov/pubmed/25853013. DOI: 10.1186/s13550−015−0085−3.